Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Motzer, R. J.
Right arrow Articles by Mazumdar, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Motzer, R. J.
Right arrow Articles by Mazumdar, M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
Journal of Clinical Oncology, Vol 20, Issue 1 (January), 2002: 289-296
© 2002 American Society for Clinical Oncology

Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell Carcinoma

By Robert J. Motzer, Jennifer Bacik, Barbara A. Murphy, Paul Russo, Madhu Mazumdar

From the Genitourinary Oncology Service, Division of Solid Tumor Oncology, and Departments of Medicine, Epidemiology and Biostatistics, and Urology, Memorial Sloan-Kettering Cancer Center; and Department of Medicine, Cornell University Medical College, New York, NY; and Vanderbilt University, Nashville, TN.

Address reprint requests to Robert J. Motzer, MD, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021; email: motzerr{at}mskcc.org

PURPOSE: To define outcome data and prognostic criteria for patients with metastatic renal cell carcinoma (RCC) treated with interferon-alfa as initial systemic therapy. The data can be applied to design and interpretation of clinical trials of new agents and treatment programs against this refractory malignancy.

PATIENTS AND METHODS: Four hundred sixty-three patients with advanced RCC administered interferon-{alpha} as first-line systemic therapy on six prospective clinical trials were the subjects of this retrospective analysis. Three risk categories for predicting survival were identified on the basis of five pretreatment clinical features by a stratified Cox proportional hazards model.

RESULTS: The median overall survival time was 13 months. The median time to progression was 4.7 months. Five variables were used as risk factors for short survival: low Karnofsky performance status, high lactate dehydrogenase, low serum hemoglobin, high corrected serum calcium, and time from initial RCC diagnosis to start of interferon-{alpha} therapy of less than one year. Each patient was assigned to one of three risk groups: those with zero risk factors (favorable risk), those with one or two (intermediate risk), and those with three or more (poor risk). The median time to death of patients deemed favorable risk was 30 months. Median survival time in the intermediate-risk group was 14 months. In contrast, the poor-risk group had a median survival time of 5 months.

CONCLUSION: Progression-free and overall survival with interferon-{alpha} treatment can be compared with new therapies in phase II and III clinical investigations. The prognostic model is suitable for risk stratification of phase III trials using interferon-{alpha} as the comparative treatment arm.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Jpn J Clin OncolHome page
N. Shinohara, A. Kumagai, K. Kanagawa, S. Maruyama, T. Abe, A. Sazawa, and K. Nonomura
Multicenter Phase II Trial of Combination Therapy with Meloxicam, a COX-2 Inhibitor, and Natural Interferon-{alpha} for Metastatic Renal Cell Carcinoma
Jpn. J. Clin. Oncol., November 1, 2009; 39(11): 720 - 726.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. J. Montero, C. M. Diaz-Montero, R. E. Millikan, J. Liu, K.-A. Do, S. Hodges, E. Jonasch, B. W. McIntyre, P. Hwu, and N. Tannir
Cytokines and angiogenic factors in patients with metastatic renal cell carcinoma treated with interferon-{alpha}: association of pretreatment serum levels with survival
Ann. Onc., October 1, 2009; 20(10): 1682 - 1687.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. Escudier, J. Roigas, S. Gillessen, U. Harmenberg, S. Srinivas, S. F. Mulder, G. Fountzilas, C. Peschel, P. Flodgren, E. C. Maneval, et al.
Phase II Study of Sunitinib Administered in a Continuous Once-Daily Dosing Regimen in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma
J. Clin. Oncol., September 1, 2009; 27(25): 4068 - 4075.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. J. Motzer, T. E. Hutson, P. Tomczak, M. D. Michaelson, R. M. Bukowski, S. Oudard, S. Negrier, C. Szczylik, R. Pili, G. A. Bjarnason, et al.
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
J. Clin. Oncol., August 1, 2009; 27(22): 3584 - 3590.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. J. Motzer and A. M. Molina
Targeting Renal Cell Carcinoma
J. Clin. Oncol., July 10, 2009; 27(20): 3274 - 3276.
[Full Text] [PDF]

Home page
 JCOHome page
B. I. Rini
Metastatic Renal Cell Carcinoma: Many Treatment Options, One Patient
J. Clin. Oncol., July 1, 2009; 27(19): 3225 - 3234.
[Abstract] [Full Text] [PDF]

Home page
 Anticancer ResHome page
M. SCHMIDINGER, A. BOJIC, U. M VOGL, W. LAMM, and C. C. ZIELINSKI
Management of Cardiac Adverse Events Occurring with Sunitinib Treatment
Anticancer Res, May 1, 2009; 29(5): 1627 - 1629.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C. N. Sternberg
Expanding the boundaries of clinical practice: building on experience with targeted therapies
Ann. Onc., May 1, 2009; 20(suppl_1): i1 - i6.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P. Schoffski, R. Bukowski, P. Flodgren, and A. Ravaud
Tyrosine kinase inhibition in renal cell carcinoma and gastrointestinal stromal tumours: case reports
Ann. Onc., May 1, 2009; 20(suppl_1): i25 - i30.
[Abstract] [Full Text] [PDF]

Home page
 AM J HOSP PALLIAT CAREHome page
R. L. Barros Costa
Review Article: Targeted Therapy: Comprehensive Review
American Journal of Hospice and Palliative Medicine, April 1, 2009; 26(2): 137 - 146.
[Abstract] [PDF]

Home page
 Clin. Cancer Res.Home page
J. S. Ko, A. H. Zea, B. I. Rini, J. L. Ireland, P. Elson, P. Cohen, A. Golshayan, P. A. Rayman, L. Wood, J. Garcia, et al.
Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients
Clin. Cancer Res., March 15, 2009; 15(6): 2148 - 2157.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol PractHome page
D. Cella, J. C. Cappelleri, A. Bushmakin, C. Charbonneau, J. Z. Li, S. T. Kim, I. Chen, M. D. Michaelson, and R. J. Motzer
Quality of Life Predicts Progression-Free Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib Versus Interferon Alfa
J. Oncol. Pract, March 1, 2009; 5(2): 66 - 70.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. R. Golshayan, S. George, D. Y. Heng, P. Elson, L. S. Wood, T. M. Mekhail, J. A. Garcia, H. Aydin, M. Zhou, R. M. Bukowski, et al.
Metastatic Sarcomatoid Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Therapy
J. Clin. Oncol., January 10, 2009; 27(2): 235 - 241.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Brugarolas
In Reply
J. Clin. Oncol., December 1, 2008; 26(34): 5653 - 5654.
[Full Text] [PDF]

Home page
 JCOHome page
B. I. Rini, S. Halabi, J. E. Rosenberg, W. M. Stadler, D. A. Vaena, S.-S. Ou, L. Archer, J. N. Atkins, J. Picus, P. Czaykowski, et al.
Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206
J. Clin. Oncol., November 20, 2008; 26(33): 5422 - 5428.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Schmidinger, C. C. Zielinski, U. M. Vogl, A. Bojic, M. Bojic, C. Schukro, M. Ruhsam, M. Hejna, and H. Schmidinger
Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma
J. Clin. Oncol., November 10, 2008; 26(32): 5204 - 5212.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. H. Finke, B. Rini, J. Ireland, P. Rayman, A. Richmond, A. Golshayan, L. Wood, P. Elson, J. Garcia, R. Dreicer, et al.
Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients
Clin. Cancer Res., October 15, 2008; 14(20): 6674 - 6682.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
T. E. Hutson, R. A. Figlin, J. G. Kuhn, and R. J. Motzer
Targeted Therapies for Metastatic Renal Cell Carcinoma: An Overview of Toxicity and Dosing Strategies
Oncologist, October 1, 2008; 13(10): 1084 - 1096.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. van Cruijsen, A. A.M. van der Veldt, L. Vroling, D. Oosterhoff, H. J. Broxterman, R. J. Scheper, G. Giaccone, J. B.A.G. Haanen, A. J.M. van den Eertwegh, E. Boven, et al.
Sunitinib-Induced Myeloid Lineage Redistribution in Renal Cell Cancer Patients: CD1c+ Dendritic Cell Frequency Predicts Progression-Free Survival
Clin. Cancer Res., September 15, 2008; 14(18): 5884 - 5892.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. A. Garcia and D. Danielpour
Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies
Mol. Cancer Ther., June 1, 2008; 7(6): 1347 - 1354.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol PractHome page
R. M. Bukowski
How I Treat Renal Cell Carcinoma
J. Oncol. Pract, May 1, 2008; 4(3): 150 - 152.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. A.M. van der Veldt, M. R. Meijerink, A. J.M. van den Eertwegh, A. Bex, G. de Gast, J. B.A.G. Haanen, and E. Boven
Sunitinib for Treatment of Advanced Renal Cell Cancer: Primary Tumor Response
Clin. Cancer Res., April 15, 2008; 14(8): 2431 - 2436.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. I. Rini
Temsirolimus, an Inhibitor of Mammalian Target of Rapamycin
Clin. Cancer Res., March 1, 2008; 14(5): 1286 - 1290.
[Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
W. K. Rathmell, W. M. Stadler, and B. I. Rini
Rational Therapeutic Choices and Strategies for Patients with Metastatic Renal Cancer
ASCO Educational Book, January 1, 2008; 2008(1): 192 - 198.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Ebbinghaus, M. Hussain, N. Tannir, M. Gordon, A. A. Desai, R. A. Knight, R. A. Humerickhouse, J. Qian, G. B. Gordon, and R. Figlin
Phase 2 Study of ABT-510 in Patients with Previously Untreated Advanced Renal Cell Carcinoma
Clin. Cancer Res., November 15, 2007; 13(22): 6689 - 6695.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Mego, M. Reckova, J. Obertova, Z. Sycova-Mila, K. Brozmanova, and J. Mardiak
Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma
Ann. Onc., November 1, 2007; 18(11): 1906 - 1907.
[Full Text] [PDF]

Home page
 JCOHome page
R. M. Bukowski, F. F. Kabbinavar, R. A. Figlin, K. Flaherty, S. Srinivas, U. Vaishampayan, H. A. Drabkin, J. Dutcher, S. Ryba, Q. Xia, et al.
Randomized Phase II Study of Erlotinib Combined With Bevacizumab Compared With Bevacizumab Alone in Metastatic Renal Cell Cancer
J. Clin. Oncol., October 10, 2007; 25(29): 4536 - 4541.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. J. Motzer, G. R. Hudes, B. D. Curti, D. F. McDermott, B. J. Escudier, S. Negrier, B. Duclos, L. Moore, T. O'Toole, J. P. Boni, et al.
Phase I/II Trial of Temsirolimus Combined With Interferon Alfa for Advanced Renal Cell Carcinoma
J. Clin. Oncol., September 1, 2007; 25(25): 3958 - 3964.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. A. Gollob, W. K. Rathmell, T. M. Richmond, C. B. Marino, E. K. Miller, G. Grigson, C. Watkins, L. Gu, B. L. Peterson, and J. J. Wright
Phase II Trial of Sorafenib Plus Interferon Alfa-2b As First- or Second-Line Therapy in Patients With Metastatic Renal Cell Cancer
J. Clin. Oncol., August 1, 2007; 25(22): 3288 - 3295.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. W. Ryan, B. H. Goldman, P. N. Lara Jr, P. C. Mack, T. M. Beer, C. M. Tangen, D. Lemmon, C.-X. Pan, H. A. Drabkin, and E. D. Crawford
Sorafenib With Interferon Alfa-2b As First-Line Treatment of Advanced Renal Carcinoma: A Phase II Study of the Southwest Oncology Group
J. Clin. Oncol., August 1, 2007; 25(22): 3296 - 3301.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
G. Hudes, M. Carducci, P. Tomczak, J. Dutcher, R. Figlin, A. Kapoor, E. Staroslawska, J. Sosman, D. McDermott, I. Bodrogi, et al.
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
N. Engl. J. Med., May 31, 2007; 356(22): 2271 - 2281.
[Abstract] [Full Text] [PDF]

Home page
 Protein Eng Des SelHome page
I. Rabhi-Essafi, A. Sadok, N. Khalaf, and D. M. Fathallah
A strategy for high-level expression of soluble and functional human interferon {alpha} as a GST-fusion protein in E.coli
Protein Eng. Des. Sel., May 1, 2007; 20(5): 201 - 209.
[Abstract] [Full Text] [PDF]

Home page
 CA Cancer J ClinHome page
J. A. Garcia and B. I. Rini
Recent Progress in the Management of Advanced Renal Cell Carcinoma
CA Cancer J Clin, March 1, 2007; 57(2): 112 - 125.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Cho, S. Signoretti, M. Regan, J. W. Mier, and M. B. Atkins
The Role of Mammalian Target of Rapamycin Inhibitors in the Treatment of Advanced Renal Cancer
Clin. Cancer Res., January 15, 2007; 13(2): 758s - 763s.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
R. J. Motzer, T. E. Hutson, P. Tomczak, M. D. Michaelson, R. M. Bukowski, O. Rixe, S. Oudard, S. Negrier, C. Szczylik, S. T. Kim, et al.
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
N. Engl. J. Med., January 11, 2007; 356(2): 115 - 124.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. S. Lam, A. Breda, A. S. Belldegrun, and R. A. Figlin
Evolving Principles of Surgical Management and Prognostic Factors for Outcome in Renal Cell Carcinoma
J. Clin. Oncol., December 10, 2006; 24(35): 5565 - 5575.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Parton, M. Gore, and T. Eisen
Role of Cytokine Therapy in 2006 and Beyond for Metastatic Renal Cell Cancer
J. Clin. Oncol., December 10, 2006; 24(35): 5584 - 5592.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. J. Motzer and R. M. Bukowski
Targeted Therapy for Metastatic Renal Cell Carcinoma
J. Clin. Oncol., December 10, 2006; 24(35): 5601 - 5608.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
H. Matsubara, Y. Mizutani, F. Hongo, H. Nakanishi, Y. Kimura, S. Ushijima, A. Kawauchi, T. Tamura, T. Sakata, and T. Miki
Gene therapy with TRAIL against renal cell carcinoma.
Mol. Cancer Ther., September 1, 2006; 5(9): 2165 - 2171.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. E. Eggener, O. Yossepowitch, J. A. Pettus, M. E. Snyder, R. J. Motzer, and P. Russo
Renal Cell Carcinoma Recurrence After Nephrectomy for Localized Disease: Predicting Survival From Time of Recurrence
J. Clin. Oncol., July 1, 2006; 24(19): 3101 - 3106.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. Fernandez-Rodriguez, G. L. de Argumedo, J. M. Mane, A. Munoz, J. Ferreiro, N. Fuente, and G. Lopez-Vivanco
High-Dose Interleukin-2 in Metastatic Renal Cell Carcinoma
J. Clin. Oncol., September 20, 2005; 23(27): 6797 - 6798.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Atkins, M. Regan, D. McDermott, J. Mier, E. Stanbridge, A. Youmans, P. Febbo, M. Upton, M. Lechpammer, and S. Signoretti
Carbonic Anhydrase IX Expression Predicts Outcome of Interleukin 2 Therapy for Renal Cancer
Clin. Cancer Res., May 15, 2005; 11(10): 3714 - 3721.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
R. Katz-Brull, N. M. Rofsky, M. M. Morrin, I. Pedrosa, D. J. George, M. D. Michaelson, R. P. Marquis, M. Maril, C. Noguera, and R. E. Lenkinski
Decreases in free cholesterol and fatty acid unsaturation in renal cell carcinoma demonstrated by breath-hold magnetic resonance spectroscopy
Am J Physiol Renal Physiol, April 1, 2005; 288(4): F637 - F641.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
B. I. Rini
VEGF-Targeted Therapy in Metastatic Renal Cell Carcinoma
Oncologist, March 1, 2005; 10(3): 191 - 197.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. I. Rini and E. J. Small
Biology and Clinical Development of Vascular Endothelial Growth Factor-Targeted Therapy in Renal Cell Carcinoma
J. Clin. Oncol., February 10, 2005; 23(5): 1028 - 1043.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. M. Mekhail, R. M. Abou-Jawde, G. BouMerhi, S. Malhi, L. Wood, P. Elson, and R. Bukowski
Validation and Extension of the Memorial Sloan-Kettering Prognostic Factors Model for Survival in Patients With Previously Untreated Metastatic Renal Cell Carcinoma
J. Clin. Oncol., February 1, 2005; 23(4): 832 - 841.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. F. McDermott, M. M. Regan, J. I. Clark, L. E. Flaherty, G. R. Weiss, T. F. Logan, J. M. Kirkwood, M. S. Gordon, J. A. Sosman, M. S. Ernstoff, et al.
Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma
J. Clin. Oncol., January 1, 2005; 23(1): 133 - 141.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. J. Motzer, J. Bacik, and M. Mazumdar
Prognostic Factors for Survival of Patients with Stage IV Renal Cell Carcinoma: Memorial Sloan-Kettering Cancer Center Experience
Clin. Cancer Res., September 15, 2004; 10(18): 6302S - 6303S.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. M. Bukowski, S. Negrier, and P. Elson
Prognostic Factors in Patients with Advanced Renal Cell Carcinoma: Development of an International Kidney Cancer Working Group
Clin. Cancer Res., September 15, 2004; 10(18): 6310S - 6314S.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. B. Atkins, M. Regan, and D. McDermott
Update on the Role of Interleukin 2 and Other Cytokines in the Treatment of Patients with Stage IV Renal Carcinoma
Clin. Cancer Res., September 15, 2004; 10(18): 6342S - 6346S.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. P. Dutcher
Mammalian Target of Rapamycin Inhibition
Clin. Cancer Res., September 15, 2004; 10(18): 6382S - 6387S.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J.-J. Patard, H. L. Kim, J. S. Lam, F. J. Dorey, A. J. Pantuck, A. Zisman, V. Ficarra, K.-R. Han, L. Cindolo, A. De La Taille, et al.
Use of the University of California Los Angeles Integrated Staging System to Predict Survival in Renal Cell Carcinoma: An International Multicenter Study
J. Clin. Oncol., August 15, 2004; 22(16): 3316 - 3322.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. I. Rini, S. Halabi, J. Taylor, E. J. Small, and R. L. Schilsky
Cancer and Leukemia Group B 90206: A Randomized Phase III Trial of Interferon-{alpha} or Interferon-{alpha} Plus Anti-Vascular Endothelial Growth Factor Antibody (Bevacizumab) in Metastatic Renal Cell Carcinoma
Clin. Cancer Res., April 15, 2004; 10(8): 2584 - 2586.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. B. Atkins, M. Hidalgo, W. M. Stadler, T. F. Logan, J. P. Dutcher, G. R. Hudes, Y. Park, S.-H. Liou, B. Marshall, J. P. Boni, et al.
Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma
J. Clin. Oncol., March 1, 2004; 22(5): 909 - 918.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. A. Sparano, R. Gray, B. Giantonio, P. O'Dwyer, and R. L. Comis
Evaluating Antiangiogenesis Agents in the Clinic: The Eastern Cooperative Oncology Group Portfolio of Clinical Trials
Clin. Cancer Res., February 15, 2004; 10(4): 1206 - 1211.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. J. Motzer, J. Bacik, L. H. Schwartz, V. Reuter, P. Russo, S. Marion, and M. Mazumdar
Prognostic Factors for Survival in Previously Treated Patients With Metastatic Renal Cell Carcinoma
J. Clin. Oncol., February 1, 2004; 22(3): 454 - 463.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
J. A. Sosman
Targeting of the VHL-Hypoxia-Inducible Factor-Hypoxia-Induced Gene Pathway for Renal Cell Carcinoma Therapy
J. Am. Soc. Nephrol., November 1, 2003; 14(11): 2695 - 2702.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Hernberg, P. Virkkunen, P. Bono, H. Ahtinen, H. Maenpaa, and H. Joensuu
Interferon Alfa-2b Three Times Daily and Thalidomide in the Treatment of Metastatic Renal Cell Carcinoma
J. Clin. Oncol., October 15, 2003; 21(20): 3770 - 3776.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. J. Motzer
Renal Cell Carcinoma: A Priority Malignancy for Development and Study of Novel Therapies
J. Clin. Oncol., April 1, 2003; 21(7): 1193 - 1194.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Nakanishi, Y. Mizutani, A. Kawauchi, O. Ukimura, T. Shiraishi, M. Hatano, M. Mizuno, J. Yoshida, and T. Miki
Significant Antitumoral Activity of Cationic Multilamellar Liposomes Containing Human IFN-{beta} Gene against Human Renal Cell Carcinoma
Clin. Cancer Res., March 1, 2003; 9(3): 1129 - 1135.
[Abstract] [Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2002 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online